Skip to main content
Top
Published in: Diabetologia 10/2009

Open Access 01-10-2009 | Article

Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial

Authors: D. Koya, M. Haneda, S. Inomata, Y. Suzuki, D. Suzuki, H. Makino, K. Shikata, Y. Murakami, Y. Tomino, K. Yamada, S. I. Araki, A. Kashiwagi, R. Kikkawa, on behalf of the Low-Protein Diet Study Group

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

There is currently insufficient evidence to recommend a low-protein diet for type 2 diabetic patients with diabetic nephropathy. We assessed whether a low-protein diet could prevent the progression of diabetic nephropathy.

Methods

This was a multi-site parallel randomised controlled trial for prevention of diabetic nephropathy progression among 112 Japanese type 2 diabetic patients with overt nephropathy. It was conducted in Japan from 1 December 1997 to 30 April 2006. The participants were randomly assigned using a central computer-generated schedule to either low-protein diet (0.8 g kg−1 day−1) and normal-protein diet (1.2 g kg−1 day−1), and were followed for 5 years. The participants and investigators were not blinded to the assignment. The primary outcomes were the annual change in estimated GFR and creatinine clearance, the incidence of doubling of serum creatinine and the time to doubling of baseline serum creatinine.

Results

The study was completed by 47 (84%) of 56 participants in the low-protein diet group and 41 (73%) of 56 participants in the normal-diet group. During the study period, the difference in mean annual change in estimated GFR between the low-protein diet and the normal-protein diet groups was −0.3 ml min−1 1.73 m−2 (95% CI −3.9, 4.4; p = 0.93). The difference in mean annual change in creatinine clearance between the low-protein diet and the normal-protein diet groups was −0.006 ml s−1 1.73 m−2 (95% CI −0.089, 0.112; p = 0.80). A doubling of serum creatinine was reached in 16 patients of the low-protein group (34.0%), compared with 15 in the normal-protein group (36.6%), the difference between groups being −2.6% (95% CI −22.6, 17.5; p = 0.80). The time to doubling of serum creatinine was similar in both groups (p = 0.66).

Conclusions/interpretation

It is extremely difficult to get patients to follow a long-term low-protein diet. Although in the low-protein group overall protein intake was slightly (but not significantly) lower, it did not confer renoprotection.
Clinical trial registration: ClinicalTrials.gov NCT00448526
Funding: Research grant from the Ministry of Health, Labour and Welfare of Japan
Appendix
Available only for authorised users
Literature
1.
go back to reference Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133PubMedCrossRef Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133PubMedCrossRef
3.
go back to reference Nakai S, Masakane I, Akiba T et al (2008) An overview of dialysis treatment in Japan (as of Dec. 31, 2006). J Jpn Soc Dial Ther 41:1–28CrossRef Nakai S, Masakane I, Akiba T et al (2008) An overview of dialysis treatment in Japan (as of Dec. 31, 2006). J Jpn Soc Dial Ther 41:1–28CrossRef
4.
go back to reference Sasso FC, De Nicola L, Carbonara O et al (2006) Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 29:498–503PubMedCrossRef Sasso FC, De Nicola L, Carbonara O et al (2006) Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 29:498–503PubMedCrossRef
5.
go back to reference Mandayam S, Mitch WE (2006) Dietary protein restriction benefits patients with chronic kidney disease. Nephrology (Carlton) 11:53–57CrossRef Mandayam S, Mitch WE (2006) Dietary protein restriction benefits patients with chronic kidney disease. Nephrology (Carlton) 11:53–57CrossRef
6.
go back to reference Kasiske BL, Lakatua JD, Ma JZ, Louis TA (1998) A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954–961PubMedCrossRef Kasiske BL, Lakatua JD, Ma JZ, Louis TA (1998) A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954–961PubMedCrossRef
7.
go back to reference Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Int Med 124:627–632PubMed Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Int Med 124:627–632PubMed
8.
go back to reference Association AD (2008) Nutritional recommendations and interventions for diabetes. A position statement of the American Diabetes Association. Diabetes Care 30(Suppl 1):S61–S78CrossRef Association AD (2008) Nutritional recommendations and interventions for diabetes. A position statement of the American Diabetes Association. Diabetes Care 30(Suppl 1):S61–S78CrossRef
9.
go back to reference Johnson DW (2006) Dietary protein restriction as a treatment for slowing chronic kidney disease progression: the case against. Nephrology (Carlton) 11:58–62CrossRef Johnson DW (2006) Dietary protein restriction as a treatment for slowing chronic kidney disease progression: the case against. Nephrology (Carlton) 11:58–62CrossRef
10.
go back to reference Robertson L, Waugh N, Robertson A (2007) Protein restriction for diabetic renal disease. Cochrane Database Syst Rev (4): Art. no. CD002181. doi:10.1002/14651858. Robertson L, Waugh N, Robertson A (2007) Protein restriction for diabetic renal disease. Cochrane Database Syst Rev (4): Art. no. CD002181. doi:10.​1002/​14651858.
11.
go back to reference Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330:877–884PubMedCrossRef Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330:877–884PubMedCrossRef
12.
go back to reference Levey AS, Greene T, Beck GJ et al (1999) Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 10:2426–2439PubMed Levey AS, Greene T, Beck GJ et al (1999) Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 10:2426–2439PubMed
13.
go back to reference Levey AS, Greene T, Sarnak MJ et al (2006) Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 48:879–888PubMedCrossRef Levey AS, Greene T, Sarnak MJ et al (2006) Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 48:879–888PubMedCrossRef
14.
go back to reference The resources council of the science and technology agency of Japan (1983) Standard tables of food composition in Japan, 4th edn. Printing Bureau, Ministry of Finance, Tokyo The resources council of the science and technology agency of Japan (1983) Standard tables of food composition in Japan, 4th edn. Printing Bureau, Ministry of Finance, Tokyo
15.
go back to reference Maroni BJ, Steinman TI, Mitch WE (1985) A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58–65PubMedCrossRef Maroni BJ, Steinman TI, Mitch WE (1985) A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58–65PubMedCrossRef
16.
go back to reference Imai E, Horio M, Nitta K et al (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50PubMedCrossRef Imai E, Horio M, Nitta K et al (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50PubMedCrossRef
17.
go back to reference Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
18.
go back to reference Pijls LT, de Vries H, Donker AJ, van Eijk JT (1999) The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transpl 14:1445–1453CrossRef Pijls LT, de Vries H, Donker AJ, van Eijk JT (1999) The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transpl 14:1445–1453CrossRef
19.
go back to reference Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH (1999) Low protein diet and kidney function in insulin dependent diabetic patients with diabetic nephropathy. Kidney Int 55:621–628PubMedCrossRef Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH (1999) Low protein diet and kidney function in insulin dependent diabetic patients with diabetic nephropathy. Kidney Int 55:621–628PubMedCrossRef
20.
go back to reference Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145–1151PubMedCrossRef Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145–1151PubMedCrossRef
21.
go back to reference Menon V, Kopple JD, Wang X et al (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Diasease (MDRD) Study. Am J Kidney Dis 53:208–217PubMedCrossRef Menon V, Kopple JD, Wang X et al (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Diasease (MDRD) Study. Am J Kidney Dis 53:208–217PubMedCrossRef
22.
go back to reference Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42:263–285PubMedCrossRef Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42:263–285PubMedCrossRef
23.
go back to reference Simonson DC (1988) Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 11:821–827PubMedCrossRef Simonson DC (1988) Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 11:821–827PubMedCrossRef
25.
go back to reference Ritz E, Dikow R (2006) Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2:562–567PubMedCrossRef Ritz E, Dikow R (2006) Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2:562–567PubMedCrossRef
26.
go back to reference KDOQI (2007) KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49(Suppl 2):S1–S179 KDOQI (2007) KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49(Suppl 2):S1–S179
27.
go back to reference Khan NA, Hemmelgarn B, Herman RJ et al (2008) The 2008 Canadian hypertension education program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 24:465–475PubMed Khan NA, Hemmelgarn B, Herman RJ et al (2008) The 2008 Canadian hypertension education program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 24:465–475PubMed
28.
go back to reference Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652–659PubMed Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652–659PubMed
29.
go back to reference Hostetter TH, Meyer TW, Rennke HG, Brenner BM (1986) Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509–517PubMedCrossRef Hostetter TH, Meyer TW, Rennke HG, Brenner BM (1986) Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509–517PubMedCrossRef
30.
go back to reference Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Collaborative Study Group: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Collaborative Study Group: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRef
31.
go back to reference Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
32.
go back to reference Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
33.
go back to reference Gæde P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef Gæde P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef
34.
go back to reference Bakris GL, Williams M, Dworkin L et al (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis 36:646–661PubMed Bakris GL, Williams M, Dworkin L et al (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis 36:646–661PubMed
35.
go back to reference Kimmel PL (2006) Update in nephrology and hypertension. Ann Int Med 144:281–285PubMed Kimmel PL (2006) Update in nephrology and hypertension. Ann Int Med 144:281–285PubMed
36.
go back to reference Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446CrossRef Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446CrossRef
Metadata
Title
Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial
Authors
D. Koya
M. Haneda
S. Inomata
Y. Suzuki
D. Suzuki
H. Makino
K. Shikata
Y. Murakami
Y. Tomino
K. Yamada
S. I. Araki
A. Kashiwagi
R. Kikkawa
on behalf of the Low-Protein Diet Study Group
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1467-8

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine